AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03443427 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NTHi Mcat investigational vaccine (GSK3277511A)
Description: Two doses administered intramuscularly at Day 1 and Day 61 in the deltoid region of the non-dominant arm and a third dose administered at either Day 181 or Day 361, according to each vaccination scheduling defined per protocol.
Study NCT03443427 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One dose administered intramuscularly at either Day 181 or Day 361 in the deltoid region of the non-dominant arm.
Study NCT00599638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabalin
Description: 75mg bid titrating to 150mg bid on day 4
Study NCT00599638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin/PF-00489791
Description: Pregabalin 75mg bid titrating to 150mg bid on day 4; PF-00489791: 4mg od titrating to 10mg od on day 4
Study NCT00599638 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02209623 — intervention group
Intervention type: BIOLOGICAL
Intervention: TDAP
Study NCT01435837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C2 (200mg of caffeine; 1/2 L of water)
Description: 200mg of caffeine (tablet); 1/2 of water
Study NCT01435837 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: C2 (200mg of caffeine; 1/2 L of water)
Description: 200mg of caffeine (tablet); 1/2 of water
Study NCT01435837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C3(200mg of caffeine; 1 L of water)
Description: Ingestion of 200 mg of caffeine and 1 Liter of water after between pretest and posttest.
Study NCT01435837 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: C3(200mg of caffeine; 1 L of water)
Description: Ingestion of 200 mg of caffeine and 1 Liter of water after between pretest and posttest.
Study NCT01435837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C1 (200mg of caffeine, no water)
Description: Ingestion of 200mg of caffeine (tablet); no water ingestion.
Study NCT02717208 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HL036
Study NCT00805675 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir
Description: Tenofovir disoproxil fumarate was supplied in 300 mg tablets
Study NCT00805675 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telbivudine plus tenofovir
Description: Telbivudine 600 mg and Tenofovir 300 mg were purchased in commercial packs. Patients were instructed to take medication(s) orally every morning either with or without food.
Study NCT05500950 — intervention group
Intervention type: OTHER
Intervention: CDU and CT-DCG or CT examination
Description: patients with space occupying lesions in the lacrimal sac area completed CDU and CT-DCG or CT examination before surgery
Study NCT01435837 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: C1 (200mg of caffeine, no water)
Description: Ingestion of 200mg of caffeine (tablet); no water ingestion.
Study NCT03739112 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent VLP Vaccine
Description: Single dose of a 30 µg/strain of Quadrivalent VLP Vaccine
Study NCT03739112 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix Quadrivalent® Comparator Vaccine
Description: Single dose of a 15 μg/strain of Fluarix Quadrivalent® Comparator Vaccine
Study NCT01047956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone; NAC
Description: Methadone NAC
Study NCT01047956 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Methadone
Study NCT02618434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPN-810 (18 mg)
Description: Subjects were randomized to receive SPN-810 9 mg twice each day with food, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if afternoon, the evening dose.
Study NCT02618434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPN-810 (36 mg)
Description: Subjects were randomized to receive SPN-810 18 mg twice each day with food, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if afternoon, the evening dose.
Study NCT02618434 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects were randomized to receive Placebo twice each day with food, in the morning and in the evening, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if afternoon, the evening dose.
Study NCT01435837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (no caffeine, no water).
Description: No ingestion of caffeine; no ingestion of water between pretest and posttest.
Study NCT01435837 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (no caffeine, no water).
Description: No ingestion of caffeine; no ingestion of water between pretest and posttest.
Study NCT03959202 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ELDERFITNESS
Description: In-person training with the exercise trainer ( 3 sessions for participants without cognitive impairments over 24 weeks \& 4 sessions for older adults with mild cognitive impairment over 16 weeks). Self-monitoring level of physical activity (steps \& minutes of moderate activity) using the smart watch. . The Google calendar and Fitbit apps will send messages and alerts to the subject's smart watch that encourage subjects to achieve subjects' daily goals. If a participant has low activity for 3 consecutive days, the research assistant will call the participant to either encourage the participant to adhere to the plan or provide a modified plan after consulting the exercise trainer. Phone consultation: Subjects will have biweekly phone consultation with the research team members to receive guidance and adjustment on activity plans.Financial incentives: when the daily activity goal is achieved for more than four days per week, a $5 reward will be given to subjects.
Study NCT03959202 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: General Education on physical activity for older adults and continue daily activity and healthcare routine. Participants will also receive a Go4Life Program book from the National Institute on Aging
Study NCT01480193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrative Medicine Therapies and Sound Based Education Therapies
Description: 3 Cognitive Based Therapy Sessions, 9 Telephonic Health Coaching Sessions, 5 Acupuncture Sessions, and Group-Based 8 week Mindfulness Based Stress Reduction Provided synergistically through an integrative medicine paradigm
Study NCT00954356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XPF-001
Description: Single oral administration of 500 mg XPF-001 capsules (5 x 100 mg capsules)
Study NCT02717208 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle
Study NCT01257724 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SHARE (Synthesized HIV/AIDS Research Evidence)
Description: SHARE (Synthesized HIV/AIDS Research Evidence) consists of several components:~1. an online searchable database of HIV-relevant systematic reviews;~2. monthly email updates highlighting new reviews;~3. access to user-friendly summaries produced by us or by others (when available);~4. links to scientific abstracts;~5. peer relevance assessments, which involves periodic requests to complete a brief assessment of how useful the information in the newly added review is with the average score posted once an assessment is completed;~6. an interface for participants to leave comments in the records of systematic reviews in the database;~7. links to full-text articles (when publicly available); and~8. access to worksheets that help CBOs find and use research evidence
Study NCT01257724 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SHARE (Synthesized HIV/AIDS Research Evidence)
Description: SHARE (Synthesized HIV/AIDS Research Evidence) consists of several components:~1. an online searchable database of HIV-relevant systematic reviews;~2. monthly email updates highlighting new reviews;~3. access to user-friendly summaries produced by us or by others (when available);~4. links to scientific abstracts;~5. peer relevance assessments, which involves periodic requests to complete a brief assessment of how useful the information in the newly added review is with the average score posted once an assessment is completed;~6. an interface for participants to leave comments in the records of systematic reviews in the database;~7. links to full-text articles (when publicly available); and~8. access to worksheets that help CBOs find and use research evidence
Study NCT02214095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glucosamine sulphate
Description: group I (G1) patients received 500 mg glucosamine sulphate capsules (Glucosamine Compound) , three times daily for 3 months following initial cause related therapy. Group II patients were given placebo capsules( Lactose) for the same period following initial cause related therapy
Study NCT02214095 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lactose capsules
Study NCT02984371 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting
Study NCT02984371 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary artery bypass grafting
Study NCT02984371 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epicardial ganglionated plexi ablation
Study NCT02984371 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: implantable loop recorder
Study NCT02984371 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implantable loop recorder
Study NCT02768753 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The Axillary Bilateral-breast Approach
Study NCT02626117 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LASER deepithelialization
Description: the selected participants were assigned in test and control. Under LA full thickness flap was reflected until the mucogingival junction and recipient area was prepared. The connective tissue graft harvested from palate was placed on the root surface and secured with 5-0 absorbable sutures. Diode (GaAlAs) laser with a wavelength of 820 nm and a power of 1.5 watt in a continuous mode was applied to remove the sulcular epithelium. The connective tissue graft was placed on the root surface at the level of the CEJ and then secured with 5-0 absorbable sutures in both test and control sites using sling suture..
Study NCT02768753 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The bilateral Axillo-breast Approach
Study NCT04080323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinoprostone 3 mg
Description: 1 vaginal tablet of 3mg dinoprostone 60 minutes before surgery
Study NCT04080323 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 vaginal tablet of placebo 60 minutes before surgery
Study NCT03329261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: COPIGREL® - clopidogrel dosed at 75 mg per tablet
Study NCT01987583 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wet cupping
Description: Wet cupping is the process of using a vacuum at different points on the body in order to gather the blood in that area. Then apply few superficial incisions (small, light scratches using a razor) on those areas, followed by repeating the vacuum on the same areas in order to remove 'harmful' blood which lies just beneath the surface of the skin.
Study NCT01987583 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: According to Saudi Hypertension management guidelines, hypertension patients may require life style modification alone , especially for newly diagnosed cases, or my require life style modification and drug treatment. This will be decided by the treating team in the hospital.
Study NCT02626117 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham LASER deepithelialization
Description: the selected participants were assigned in test and control. Under LA full thickness flap was reflected until the mucogingival junction and recipient area was prepared. The connective tissue graft harvested from palate was placed on the root surface and secured with 5-0 absorbable sutures. sham LASER deepithelialisation was applied to the sulcular epithelium. The connective tissue graft was placed on the root surface at the level of the CEJ and then secured with 5-0 absorbable sutures in both test and control sites using sling suture..
Study NCT01987583 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: According to Saudi Hypertension management guidelines, hypertension patients may require life style modification alone , especially for newly diagnosed cases, or my require life style modification and drug treatment. This will be decided by the treating team in the hospital.
Study NCT04415632 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low glycemic index diet
Description: • Three-day cycle menu of LGI diet will be designed and supplied to each participant in an amount designed to meet their estimated energy requirements. The percentage energy from protein, fat and carbohydrate will be the same in the two diets. Each diet period of the trial will last for two weeks.
Study NCT04415632 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: High glycemic index diet
Description: Three-day cycle menu of HGI diet will be designed and supplied to each participant in an amount designed to meet their estimated energy requirements. The percentage energy from protein, fat and carbohydrate will be the same in the two diets. Each diet period of the trial will last for two weeks.
Study NCT01591291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron + Brief Behavioral Enhancement Treatment
Description: Ondansetron 4ug/kg twice daily
Study NCT01591291 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Brief Behavioral Enhancement Treatment
Description: Placebo twice daily
Study NCT03179150 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Computed Tomography
Description: CT scans were performed on a 128 detector rows CT scanner (Somatom Definition Flash Siemens Medical Systems, Erlangen, Germany) as in routine clinical practice in the centre
Study NCT02342340 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Navy Beans (cooked)
Description: One time consumption of 3/4 cup of cooked navy beans.
Study NCT02342340 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Red Kidney Beans (cooked)
Description: One time consumption of 3/4 cup of cooked red kidney beans.
Study NCT02342340 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pinto Beans (cooked
Description: One time consumption of 3/4 cup of cooked pinto beans.
Study NCT02342340 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Black Beans (cooked)
Description: One time consumption of 3/4 cup of cooked black beans.
Study NCT02342340 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lentils (cooked)
Description: One time consumption of 3/4 cup of cooked lentils.
Study NCT02342340 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: White Rice
Description: One time consumption of 3/4 cup of cooked white rice.
Study NCT04226066 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T601
Description: Part1: T601 is injected once (Day1). Dose range: 1E+7, 3E+7, 1E+8, 3E+8, 1E+9pfu.Trial cycle: Day1-21.~For part1, 3+3 dose-escalation. After all patients of one dosage finished DLT evaluation, investigator judged that patients can benefit from treatment and no intolerable toxicity occurred, patients could receive maintenance treatment, and treatment plan is same as Cycle 1.
Study NCT04226066 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: T601+5-FC
Description: Part2: T601 is injected once (Day1). Dose range: MTD-2, MTD-1 and MTD of Part1. 5-FC is taken on Day5-18 for 14 consecutive days. Trial cycle: Day1-28.~Part3: T601 is injected 3 times (Day1, 8, 15). Dose range: MTD-1 and MTD, or MTD-2 and MTD-1 of Part2. 5-FC is taken on Day5-7, Day12-14 and Day19-32. Trial cycle: Day1-46.~Part4: Protocol revised based on results of Part1-Part3. Preliminary plan: 30 patients with gastric cancer, pancreatic cancer and hepatocellular cancer who have failed standard therapeutic options are enrolled (10 patients for each indication). Treatment plan is same as Part3.~For part2 and part3, 3+3 dose-escalation. After all patients of one dosage finished DLT evaluation, investigator judged that patients can benefit from treatment and no intolerable toxicity occurred, patients could receive maintenance treatment, and treatment plan is same as Cycle 1.
Study NCT02508493 — intervention group
Intervention type: OTHER
Intervention: THINC-it Tool
Description: Digitalized cognitive test application administering the following cognitive test components:~* Digit Symbol Substitution Test (DSST)~* Choice Reaction Time (CRT)~* One-back working memory tool~* Trail Making Test B (TMT-B)~* Perceived Deficits Questionnaire-5 Depression (PDQ-5-D)
Study NCT04347148 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SNAGs Treatment
Description: a sustained passive accessory movement (glide), i.e. SNAGs, will be applied by the physiotherapist while the participant will be asked to move actively as allowed by his/her physiological range in the direction producing his symptoms.
Study NCT04347148 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Laser Treatment
Description: A Laser YAG 3 Chronic (Winform Medical Engineering s.r.l., San Donà di Piave (VE), Italy), will be detuned and applied in the region of cervical spine in order to have a sham treatment
Study NCT03980236 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Livongo-Insulia Study App
Description: Throughout the study, participants will be asked to use the LIvongo-Insulia Study App daily to receive their basal insulin dose recommendation. Participants will need to check their before breakfast blood glucose using their Livongo meter. Then, they will need to open the Livongo-Insulia Study App and accept the uploaded blood glucose(s) from the Livongo meter. Once the appropriate information is received, participants will receive an insulin dose recommendation and should confirm once the dose has been taken. Depending on their blood glucose, participants may also receive coaching messages and coaching support from the Livongo program.
Study NCT01780428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CL-108 (hydrodocone 7.5 mg, acetaminophen 325 mg, promethazine 12.5 mg)
Study NCT01780428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CL-108 (hydrodocone 7.5 mg, acetaminophen 325 mg, promethazine 12.5 mg)
Study NCT01780428 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01204879 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Participants earn the chance to win prizes for the targeted behavior.
Study NCT01204879 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contingency Management
Description: Participants earn the chance to win prizes for the targeted behavior.
Study NCT00915915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol/Gestodene (BAY86-5016)
Description: Transdermal patch: 0.55mg Ethinylestradiol (EE+2.1mg GSD)Gestodene; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles), 1 Follow - up cycle)
Study NCT00915915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol/Gestodene (BAY86-5016)
Description: Transdermal patch: 0.55mg Ethinylestradiol (EE+1.05mg GSD)Gestodene; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles), 1 Follow - up cycle)
Study NCT00954356 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Single oral administration of 5 x 100 mg Placebo capsules.
Study NCT02399072 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention administered in this study
Study NCT02122965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist-led medication review
Description: Medication review is a structured, critical examination of a patient's medications with the objective of reaching agreement with the patient about treatment, optimizing the medications' impact, and minimizing the number of medication-related problems and adverse drug events.
Study NCT02251574 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Calorie Diet
Description: Weight management program designed around a low calorie diet.
Study NCT02251574 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very Low Calorie Diet
Description: Weight management program designed around a very low calorie diet.
Study NCT02251574 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Care provided that would normally be given to people meeting eligibility criteria for this study.
Study NCT00187148 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: EnvDNA
Description: administered as 100 mcg of DNA in 1.5mL PBS every 28 days for 3 injections
Study NCT04126187 — intervention group
Intervention type: DEVICE
Intervention: Panoptix
Description: Panoptix trifocal intraocular lens (IOL)